

EDITORS | RICHARD A. STOREY | INGVAR YMÉN

# Solid State Characterization of Pharmaceuticals



 WILEY



# **Solid State Characterization of Pharmaceuticals**



# Solid State Characterization of Pharmaceuticals

Editors

RICHARD A. STOREY

*AstraZeneca R&D, Macclesfield, UK*

INGVAR YMÉN

*AstraZeneca R&D, Södertälje, Sweden*

 **WILEY**

A John Wiley & Sons, Ltd., Publication

This edition first published 2011  
© 2011 Blackwell Publishing

*Registered office*

John Wiley & Sons Ltd, The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, United Kingdom

For details of our global editorial offices, for customer services and for information about how to apply for permission to reuse the copyright material in this book please see our website at [www.wiley.com](http://www.wiley.com).

The right of the author to be identified as the author of this work has been asserted in accordance with the Copyright, Designs and Patents Act 1988.

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, except as permitted by the UK Copyright, Designs and Patents Act 1988, without the prior permission of the publisher.

Wiley also publishes its books in a variety of electronic formats. Some content that appears in print may not be available in electronic books.

Designations used by companies to distinguish their products are often claimed as trademarks. All brand names and product names used in this book are trade names, service marks, trademarks or registered trademarks of their respective owners. The publisher is not associated with any product or vendor mentioned in this book. This publication is designed to provide accurate and authoritative information in regard to the subject matter covered. It is sold on the understanding that the publisher is not engaged in rendering professional services. If professional advice or other expert assistance is required, the services of a competent professional should be sought.

The publisher and the author make no representations or warranties with respect to the accuracy or completeness of the contents of this work and specifically disclaim all warranties, including without limitation any implied warranties of fitness for a particular purpose. This work is sold with the understanding that the publisher is not engaged in rendering professional services. The advice and strategies contained herein may not be suitable for every situation. In view of ongoing research, equipment modifications, changes in governmental regulations, and the constant flow of information relating to the use of experimental reagents, equipment, and devices, the reader is urged to review and evaluate the information provided in the package insert or instructions for each chemical, piece of equipment, reagent, or device for, among other things, any changes in the instructions or indication of usage and for added warnings and precautions. The fact that an organization or Website is referred to in this work as a citation and/or a potential source of further information does not mean that the author or the publisher endorses the information the organization or Website may provide or recommendations it may make. Further, readers should be aware that Internet Websites listed in this work may have changed or disappeared between when this work was written and when it is read. No warranty may be created or extended by any promotional statements for this work. Neither the publisher nor the author shall be liable for any damages arising herefrom.

*Library of Congress Cataloging-in-Publication Data*

Solid state characterization of pharmaceuticals / edited by Richard A. Storey, Ingar Ymén.  
p. ; cm.

Includes bibliographical references and index.

ISBN 978-1-4051-3494-1 (cloth) – ISBN 978-0-470-65935-9 (ePDF)

1. Solid dosage forms. 2. Drugs—Design. 3. Pharmaceutical chemistry. I. Storey, Richard A. II. Ymén, Ingar. [DNLM: 1. Chemistry, Pharmaceutical. 2. Drug Design. 3. Pharmaceutical Preparations—chemistry. QV 744] RS201.S57S63 2011 615'.19—dc22

2010053725

A catalogue record for this book is available from the British Library.

Print ISBN: 9781405134941

ePDF ISBN: 9780470659359

oBook ISBN: 9780470656792

ePub ISBN: 9781119970170

eMobi ISBN: 9781119970187

Set in 9/11pt Times-Roman by Laserwords Private Limited, Chennai, India  
Printed in Great Britain by Antony Rowe Ltd, Chippenham, Wiltshire

# Contents

<i>List of Contributors</i>	xv
<i>About the Editors</i>	xvii
<i>Preface</i>	xix
<b>1. Introduction to the Solid State – Physical Properties and Processes</b>	<b>1</b>
<i>Ingvar Ymén</i>	
1.1 Introduction	1
1.1.1 The Gas/Vapour and Liquid States	1
1.1.2 The Crystalline State	3
1.1.3 The Glassy State	5
1.2 Neutral Pharmaceutical Molecules	7
1.3 Thermodynamics and Phase Diagrams	9
1.3.1 Gibbs Phase Rule	11
1.3.2 One-Component (Unary) Systems	12
1.3.3 Two-Component (Binary) Systems	13
1.3.4 Three-Component (Ternary) Systems	14
1.4 Neutral Pharmaceutical Molecules in the Solid State	15
1.5 Salt Formation and Acid-Base Equilibrium	16
1.6 Polymorphs, Solvates and Mixed Crystals	20
1.6.1 Mixed Crystals	22
1.6.2 Solvates and Hydrates	23
1.7 Phase Transitions and Kinetics	26
1.7.1 Crystallization	27
1.7.2 Solid-to-Solid Phase Transitions	29
1.8 Screening for ‘Polymorphs’ (Ansolvates and Solvates)	30
1.9 Summary	31
1.10 Acknowledgements	31
References	31
<b>2. X-Ray Diffraction</b>	<b>35</b>
<i>Chris J. Gilmore</i>	
2.1 Introduction	35
2.2 Generation and Properties of X-Rays	35
2.2.1 The Synchrotron	36
2.3 Crystal, Lattices, Unit Cells and Symmetry	37

2.3.1	Point Group Symmetry	37
2.3.2	Unit Cells and Crystal Lattices	38
2.3.3	Miller Indices	40
2.3.4	Space Group Symmetry	41
2.3.5	The Asymmetric Unit	43
2.4	The Interaction of X-rays with Crystals	44
2.4.1	X-rays and Atoms	44
2.4.2	X-Rays and Crystals	45
2.4.3	Determining Space Groups	46
2.5	Collecting Intensity Data for Single Crystals	47
2.6	Determining Crystal Structures	49
2.6.1	The Fundamental Equations of Crystallography and the Phase Problem	49
2.6.2	Data Resolution and Completeness	51
2.6.3	Methods of Solving Crystal Structures	51
2.6.4	Completing the Structure	52
2.6.5	Refinement and Validation	52
2.6.6	Small Crystals and the Synchrotron	53
2.6.7	Databases	53
2.6.8	Absolute Configuration	54
2.6.9	Polymorphism	55
2.7	Powder Diffraction	55
2.7.1	Preferred Orientation	57
2.7.2	Data Collection	58
2.7.3	Qualitative Analysis: Pattern Matching	59
2.7.4	Compositions of Mixtures: Quantitative Analysis	60
2.7.5	Structure Solution from Powders	61
2.7.6	Powder Diffraction and Polymorphs	63
2.7.7	Nonambient Conditions	65
2.8	Amorphous Powders	65
2.9	Particle Size	66
2.10	Other Radiations: Neutrons and Electrons	67
2.10.1	Neutrons	67
2.10.2	Electrons	69
	References	69
<b>3.</b>	<b>Spectroscopic Characterization</b>	<b>71</b>
	<i>Andrew O'Neil and Howell Edwards</i>	
3.1	Introduction and Theory	71
3.2	Electromagnetic Radiation	72
3.3	Vibrational Spectroscopy	74
3.3.1	Basic Instrument Configuration for Spectroscopy	75
3.4	Mid- and Near-Infrared Spectroscopy	76
3.4.1	Instrumentation	77
3.4.2	Attenuated Total Reflectance Spectrometry	78
3.4.3	Applications	79
3.4.4	Pharmaceutical Examples of the Use of ATR-FT-IR Spectroscopy	79

3.5	Near-Infrared Spectroscopy	81
3.5.1	Theory	81
3.5.2	Instrumentation	85
3.5.3	Qualitative and Quantitative Data Analysis	87
3.5.4	Pharmaceutical Applications	89
3.5.5	Polymorphism	91
3.5.6	Pseudopolymorphism, Hydrates and Solvates	91
3.5.7	Authentication of Medicines and Detection of Counterfeit and Clone Versions	92
3.5.8	Pharmaceutical Examples of the Use of NIR Spectrometry	92
3.6	Raman Spectroscopy	98
3.6.1	Theory	98
3.6.2	Instrumentation	102
3.6.3	Pharmaceutical Applications	102
3.6.4	Raman Spectrometry for Process Monitoring, Degradation, Stability and Crystallization	103
3.6.5	Polymorphism	105
3.6.6	Pseudopolymorphism	106
3.6.7	Process Analytical Technology	108
3.6.8	Raman Spectroscopy: Pharmaceutical Examples	109
3.7	Chemical Imaging and Mapping Microscopy	112
3.8	Nuclear Magnetic Resonance Spectroscopy	117
3.8.1	Pharmaceutical Applications	122
3.8.2	General Applications	122
3.8.3	Polymorphism	123
3.8.4	Drug Substance and Dosage Form Analysis	124
3.8.5	Conformation, Stereochemistry and Hydrogen Bonding Interactions	124
3.9	Terahertz Pulsed Spectroscopy	124
3.9.1	Theory	124
3.9.2	Instrumentation	124
3.9.3	Sample and Instrument Preparation	126
3.9.4	Recent Developments in Instrumentation	127
3.9.5	Pharmaceutical Applications	127
	References	130
<b>4.</b>	<b>Thermal Analysis – Conventional Techniques</b>	<b>135</b>
	<i>Mark Saunders and Paul Gabbott</i>	
4.1	Introduction	135
4.2	Differential Scanning Calorimetry (DSC)	135
4.2.1	Heat Flow Measurements	136
4.2.2	Derivative Curves	137
4.2.3	General Practical Points	137
4.2.4	Encapsulation	138
4.2.5	Temperature Range	139
4.2.6	Scan Rate	140
4.2.7	The Instrumental Transient	140

4.2.8	Calibration	140
4.2.9	Factors Affecting Calibration	142
4.2.10	Double Furnace Design	142
4.2.11	Single Furnace Designs	143
4.2.12	Differential Thermal Analysis (DTA)	144
4.2.13	Modulated Temperature Profiles	144
4.2.14	Stepwise Methods	145
4.3	Thermogravimetric Analysis (TGA)	146
4.3.1	Instrument Design	146
4.3.2	TGA Calibration	147
4.3.3	Practical Points	147
4.3.4	Sample Interpretation	148
4.4	Dynamic Mechanical Analysis (DMA)	148
4.4.1	What is DMA?	148
4.4.2	How Does a DMA Work?	150
4.5	Determining the Melting Behaviour of Crystalline Solids	154
4.5.1	Evaluating the Melting Point Transition	155
4.5.2	Melting Point Determination for Identification of Samples	155
4.6	Polymorphism	156
4.6.1	Significance of Pharmaceutical Polymorphism	156
4.6.2	Thermodynamic and Kinetic Aspects of Polymorphism: Enantiotropy and Monotropy	157
4.6.3	Characterization of Polymorphs by DSC	158
4.6.4	Determining Polymorphic Purity by DSC	161
4.6.5	Interpretation of DSC Thermograms of Samples Exhibiting Polymorphism	167
4.7	Solvates and Hydrates (Pseudopolymorphism)	168
4.7.1	Factors Influencing DSC Curves of Hydrates and Solvates	168
4.7.2	Types of Desolvation/Dehydration	170
4.8	Evolved Gas Analysis (EGA) and Simultaneous Measurements	171
4.9	Amorphous Content	174
4.9.1	Introduction	174
4.9.2	Characterization of Amorphous Solids: The Glass Transition Temperature	175
4.9.3	Quantification of Amorphous Content Using DSC	176
4.10	Purity Determination Using DSC	179
4.10.1	Types of Impurity	179
4.10.2	Differential Scanning Calorimetry Purity Method	180
4.10.3	Practical Issues and Potential Interferences	180
4.11	Excipient Compatibility	183
4.11.1	Excipient Compatibility Screening Using DSC	184
	References	184
<b>5.</b>	<b>Thermal Analysis – Dielectric Techniques</b>	<b>187</b>
	<i>Susan Barker and Milan D. Antonijevic</i>	
5.1	General Introduction	187

5.2	Common Background to the Techniques	187
5.3	Dielectric Spectroscopy	188
5.3.1	Interpretation of Data	189
5.3.2	Pharmaceutical Examples of Dielectric Spectroscopy	190
5.3.3	Analysis of Water Distribution and Mobility	191
5.3.4	Investigation of Molecular Mobility	193
5.3.5	Formulation, Characterization and Distribution of Materials	194
5.3.6	Experimental Issues	195
5.3.7	Advantages and Disadvantages of Dielectric Spectroscopy	195
5.4	Thermally Stimulated Current (TSC) Spectroscopy	196
5.4.1	Experimental Modes	196
5.4.2	Data Interpretation	198
5.4.3	Pharmaceutical Examples of the Use of TSC	199
5.4.4	Characterization of Amorphous Materials	199
5.4.5	Characterization of Polymorphic Materials	200
5.4.6	Experimental Issues	203
5.4.7	Advantages and Disadvantages of TSC	204
5.5	Overall Conclusions	204
	References	204
<b>6.</b>	<b>Isothermal Calorimetric Analysis</b>	<b>207</b>
	<i>Andrew Hills</i>	
6.1	Introduction	207
6.1.1	Driving Forces – Thermodynamics	207
6.1.2	Kinetic Factors	208
6.2	Calorimetry: Principle of Measurement	209
6.2.1	Heat Conduction Isothermal Microcalorimetry	210
6.2.2	Power Compensation Isothermal Microcalorimetry	210
6.2.3	Instrumentation and Common Experiment Methodology	211
6.2.4	Calibration	212
6.3	Applications of IM for Characterization of Solid-State Pharmaceuticals	214
6.3.1	Detection and Characterization of Disorder in Processed Materials	214
6.3.2	Production of Amorphous Forms	216
6.3.3	Method 1: Direct Detection (Measurement) of Recrystallization	217
6.3.4	Method 2: Indirect Detection of Recrystallization	219
6.4	Analysis of Solid-State Form Conversions	222
6.5	Analysis of Solid State Chemical Reactions	223
6.5.1	Solution Phase Reactions	223
6.6	Excipient Compatibility	228
	References	230
<b>7.</b>	<b>Calorimetric Methods – Solution Calorimetry</b>	<b>233</b>
	<i>Simon Gaisford</i>	
7.1	Introduction	233
7.2	The Principles of Solution Calorimetry	234

7.2.1	Semi-Adiabatic Solution Calorimeters	235
7.2.2	Heat-Conduction Calorimeters	236
7.2.3	Sample – Solvent Mixing	236
7.2.4	Calibration	237
7.3	Applications	237
7.3.1	Polymorphism	237
7.3.2	Determination of Degree of Crystallinity/Amorphous Content	239
7.3.3	Characterization of Interactions	240
7.3.4	Other Applications	240
7.4	Summary	241
	References	241
<b>8.</b>	<b>Vapour Sorption and Surface Analysis</b>	<b>245</b>
	<i>Jerry Y. Y. Heng and Daryl R. Williams</i>	
8.1	Introduction	245
8.1.1	Background	245
8.1.2	Theory of Intermolecular Forces	246
8.1.3	Thermodynamics of Interfaces	247
8.1.4	Surface Energy	250
8.1.5	Comparison of Some Surface Characterization Methods	253
8.1.6	Solid State	255
8.2	Inverse Gas Chromatography	256
8.2.1	Introduction to IGC	256
8.2.2	Experimental Methodology	257
8.2.3	Theoretical Aspects of IGC	257
8.2.4	IGC Technique	260
8.2.5	Determination of Properties of Various Crystalline Forms	261
8.2.6	Surface Properties and Powder Processing	265
8.2.7	Recent Developments	266
8.2.8	Future Applications	266
8.3	Dynamic Vapour Sorption	268
8.3.1	Introduction	268
8.3.2	Fundamentals	268
8.3.3	Dynamic Vapour Sorption Instrumentation	269
8.3.4	Characterization of Solid State Materials	270
8.3.5	Gravimetric Dynamic Vapour Sorption Instruments Hyphenated With Other Analytical Methods	272
8.3.6	Amorphous Material Studies	273
8.3.7	Solute Permeability and Diffusion of Packaging Systems	274
8.3.8	Vapour Pressure Measurement Using Knudsen Effusion	275
	References	276
<b>9.</b>	<b>Microscopy</b>	<b>287</b>
	<i>Gary Nichols, Shen Luk and Clive Roberts</i>	
9.1	Introduction	287

9.2	The Microscope as an Analytical Tool	288
9.3	Which Microscope to Use?	288
9.4	Light Microscopy	289
9.4.1	The Polarizing Light Microscope for Studying Solid-State Properties	290
9.4.2	Specimen Preparation for Light Microscopy	293
9.4.3	Characterizing Crystalline and Amorphous Materials Using Polarized Light Microscopy	294
9.4.4	Determining the Optical Properties of Crystals	295
9.4.5	Measuring the Refractive Indices of Solids	300
9.4.6	Assessing the Microsolubility of Solids	301
9.5	Crystal Shape	302
9.6	Particle Size	305
9.7	Nonambient Light Microscopy	306
9.7.1	Thermomicroscopy	307
9.7.2	Humidity Stage	315
9.7.3	Freeze-Drying Stage	316
9.7.4	Examination of Liquid Crystals Using Nonambient Light Microscopy	316
9.8	Scanning Electron Microscopy	318
9.8.1	How the SEM Works	320
9.8.2	Specimen Preparation for SEM	322
9.8.3	Electron Beam – Specimen Interactions	323
9.8.4	Environmental SEM and Variable Pressure SEM	327
9.8.5	Quantitative Analysis of SEM Images	329
9.9	Elemental X-Ray Microanalysis	330
9.9.1	Detecting X-rays	331
9.9.2	The X-ray Emission Spectrum	332
9.9.3	Energy Dispersive X-ray Microanalysis of Single Particles and Elemental Mapping	332
9.10	Atomic Force Microscopy	334
9.10.1	Atomic Force Microscopy Principle of Operation	335
9.10.2	Application of AFM to Pharmaceutical Analysis	337
9.11	Future Perspectives	346
	References	347
<b>10.</b>	<b>Particulate Analysis – Mechanical Properties</b>	<b>357</b>
	<i>Ron J. Roberts</i>	
10.1	Introduction	357
10.2	Tableting/Comminution Process	358
10.3	Indentation and Nanoindentation Testing	359
10.4	Deformation Behaviour of Powders	360
10.5	Evaluation of Deformation Behaviour and Compressibility	361
10.5.1	Density Versus Porosity During Compaction	361
10.5.2	Brittle-Ductile Transitions of Particulates During Compression	362
10.5.3	Effect of Velocity on Mechanical Properties	363
10.6	Solubility Parameters ( $\delta$ ) and Cohesive Energy Density (CED) and Mechanical Properties	363

10.6.1	Mechanical Properties	366
10.7	Influence of Crystal Structure on Mechanical Properties	369
10.8	Polymorphism and Mechanical Properties	375
10.9	Hydrates/Anhydrous	377
10.10	Salts	378
10.11	Co-crystals	380
10.12	Amorphous/Crystalline	380
10.13	Conclusion	381
	References	382
<b>11.</b>	<b>Particulate Analysis – Particle Size</b>	<b>387</b>
	<i>Xian-Ming Zeng</i>	
11.1	Introduction	387
11.2	Particle Size and Shape	388
11.3	Particle Shape Analysis	388
11.4	Particle Diameter	389
11.5	Particle Size Distribution	391
	11.5.1 Normal Distribution	391
	11.5.2 Log Normal Distribution	392
11.6	The Average Particle Size	393
	11.6.1 The Median	393
	11.6.2 The Mode	393
	11.6.3 Mean Diameters	393
	11.6.4 Range of Particle Size	394
11.7	Particle Size Measurement	395
	11.7.1 Sieve Analysis	395
	11.7.2 Microscopy and Image Analysis	396
	11.7.3 Laser Diffraction	397
	11.7.4 Electrical Sensing Zone	399
	11.7.5 Time of Flight	399
	11.7.6 Sedimentation	400
	11.7.7 Inertial Impaction	402
	11.7.8 Dynamic Light Scattering	404
	11.7.9 Single Particle Counters	405
11.8	Surface Area Measurement	406
	11.8.1 Gas Adsorption	406
	11.8.2 Permeability Methods	407
	11.8.3 Mercury Porosimetry	408
11.9	Particle Size Reduction	408
11.10	Particle Size Assessment and Pharmaceutical Development	410
	11.10.1 Sampling Issues	410
	11.10.2 Instrument Calibration and Qualification	411
	11.10.3 Selection of Particle Sizing Techniques	412
	11.10.4 Method Development and Validation	415
	11.10.5 Regulatory Considerations	417
11.11	A Case Study: Medicinal Aerosols	418

11.11.1 Particle Size and Lung Deposition	418
11.11.2 Measurement of API and Excipient Particle Size	418
11.11.3 Measurement of Aerodynamic Particle Size	419
11.11.4 Setting Up Particle Size Specifications	419
11.12 Concluding Remarks	421
References	422
<b>12. Computational Polymorph Prediction</b>	<b>427</b>
<i>Sarah L. Price and Louise S. Price</i>	
12.1 Introduction	427
12.1.1 Interpretation of Different Crystal Energy Landscapes	428
12.2 Factors Limiting the Reliability of Computed Energy Landscapes	430
12.2.1 Molecular Conformational Flexibility	430
12.2.2 The Intermolecular Forces	432
12.2.3 The Search Method	434
12.3 Are Some Crystal Structures Easier to Predict than Others?	435
12.4 Illustrative Examples of Crystal Energy Landscapes for Pharmaceuticals	437
12.4.1 Simple Case Examples of Uracils Illustrating Types of Energy Diagrams	437
12.4.2 Examples Where Computational Studies Have Aided the Discovery of New Polymorphs	438
12.4.3 Indications of Solvate Formation	440
12.4.4 Rationalization of Disorder and Complex Solid State	441
12.5 Property Prediction	442
12.6 Future Prospects	443
12.7 Acknowledgements	444
References	444
<b>13. Patenting of Inventions Relating to Polymorphs</b>	<b>451</b>
<i>Bertrand Gellie, Claire Johnson and Thomas Weisbrod</i>	
13.1 Introduction	452
13.1.1 Patenting Process	452
13.1.2 Main Patentability Criteria for Polymorph Inventions	452
13.2 Clarity	454
13.2.1 Nomenclature of Polymorphs and its Consequences (Threlfall 1995; Bernstein 2002: Chapter 1.2.3)	454
13.2.2 Clear Definition of Polymorphs in Patent Claims	455
13.2.3 Crystal Habit	457
13.2.4 Product-by-Process Definition	458
13.3 Novelty	458
13.3.1 The Novelty Requirement	458
13.3.2 The Novelty of a Polymorph	458
13.4 Inventive Step	460
13.4.1 The Requirement of Inventive Step	460
13.4.2 Determination of the Closest Prior Art	460
13.4.3 The Difference and the Resulting Technical Effect	461

13.4.4	The Objective Problem and the Step of Checking if the Problem has been Solved	461
13.4.5	The Assessment of Inventive Step	462
13.5	Sufficiency of Disclosure	464
13.6	Unity of Invention	466
13.7	Patenting Strategy	467
13.7.1	What to Patent?	467
13.7.2	When to Patent?	467
13.7.3	Dependence and Freedom of Use	468
13.7.4	Defensive Publication	468
	Notes	469
	References	469
<b>14.</b>	<b>A ‘Roadmap’ to Solid Form Selection</b>	<b>473</b>
	<i>Richard Storey</i>	
14.1	Introduction	473
14.2	Summary of Solid-Form Screening Process	475
14.2.1	Development of Amorphous Materials	477
14.2.2	Salt Screening	477
14.2.3	Vapour Diffusion	480
14.2.4	Evaporative Techniques	480
14.2.5	Scale-up and Analysis	481
14.2.6	Hydrates	483
14.2.7	Solid-State Stability	484
14.2.8	Dissolution Rate	484
14.2.9	Effects of Processing	485
14.3	Polymorph Screening	485
14.3.1	Early Polymorph Screening Prior to Nomination	485
14.3.2	Late Polymorph Screening During Development	486
14.3.3	Evaporative Techniques	487
14.3.4	Cooling Crystallization	487
14.3.5	Antisolvent Techniques	487
14.3.6	Sampling	487
14.3.7	Regulatory Guidance	489
14.4	Conclusion	490
	References	491
	<b><i>Index</i></b>	<b>493</b>

# List of Contributors

**Milan D. Antonijevic**, School of Science, University of Greenwich at Medway, Chatham Maritime, UK

**Susan Barker**, School of Pharmacy, University of East Anglia, Norwich, UK

**Howell Edwards**, Bradford University, Bradford, UK

**Paul Gabbott**, PETA Solutions and Thermal Instruments Ltd, Aylesbury, UK

**Simon Gaisford**, School of Pharmacy, University of London, London, UK

**Bertrand Gellie**, European Patent Office, Pure and Applied Organic Chemistry, Munich, Germany

**Chris J. Gilmore**, WestCHEM, Department of Chemistry, University of Glasgow, Glasgow, UK

**Jerry Y. Y. Heng**, Department of Chemical Engineering, Imperial College London, London, UK

**Andrew Hills**, Pfizer Global R&D, Sandwich, UK

**Claire Johnson**, European Patent Office, Pure and Applied Organic Chemistry, Munich, Germany

**Shen Luk**, Molecular Profiles, Nottingham, UK

**Clive Roberts**, University of Nottingham, UK

**Gary Nichols**, Pfizer Global R&D, Sandwich, UK

**Andrew O'Neil**, School of Pharmacy and Chemistry, Kingston University, London, UK

**Sarah L. Price**, University College London, London, UK

**Louise S. Price**, University College London, London, UK

**Ron J. Roberts**, AstraZeneca R&D, Macclesfield, UK

**Mark Saunders**, Kuecept Ltd, Hengoed, UK

**Richard Storey**, AstraZeneca R&D, Macclesfield, UK

**Thomas Weisbrod**, European Patent Office, Pure and Applied Organic Chemistry, Berlin, Germany

**Daryl R. Williams**, Department of Chemical Engineering, Imperial College London, London, UK and Surface Measurement Systems Limited, London, UK

**Ingvar Ymén**, AstraZeneca R&D, Södertälje, Sweden

**Xian-Ming Zeng**, TEVA Branded Pharmaceutical Products R&D, Inc., Miami, USA

# About the Editors

**Dr Richard Storey** is Principal Scientist, Pharmaceutical Development at AstraZeneca R&D, Macclesfield (Richard.a.storey@astrazeneca.com). He is a pharmacist who completed his PhD in Crystallization and Materials Science in 1997 at the University of Bradford. He then moved to the supercritical fluid crystallization SME, Bradford Particle Design, investigating the potential applications of this new technology. In 1998 he moved to Pfizer Global R&D and worked on solid form selection of new pharmaceutical molecules with a specific focus on the use of high throughput screening of solid forms. In 2003 Richard moved to AstraZeneca in Macclesfield where he has held roles in both management and scientific areas in solid state selection and materials science with a specific focus on the role of material properties on process performance. Richard is also the treasurer and board member of the Academy of Pharmaceutical Sciences of Great Britain.

**Dr Ingvar Ymén** is Principal Scientist at AstraZeneca R&D, Medicines Development, Physical Science, 151 85 Södertälje Sweden (ingvar.ymen@astrazeneca.com). He obtained his PhD in Inorganic Chemistry and Crystallography on metal-organic compounds in 1983 at the University of Lund. He then moved to Norsk Hydro Fertilizers and Explosives, where he held scientific as well as managerial positions from 1984 to 1992. There he did scientific work on heterogeneous equilibrium, including polymorphism, crystallization and reaction controlling of ammonium nitrate-containing compounds. By determining and exploring binary, ternary and quaternary phase diagrams, together with mass and energy balances, he also designed and implemented stable, continuous, large-scale, granulation and prilling processes for fertilizers and explosives. In 1992, he moved to Astra to work as a solid state scientist and became manager of the Solid State Analysis Team in Södertälje in 1995, a position he held until 2003, when he returned to a purely scientific position as principal scientist. He has remained in this role and is today involved in research on heterogeneous equilibrium, especially towards crystallization, polymorphism and salt screening. As of today he has been working in the field of heterogeneous equilibrium for more than 30 years.



# Preface

Drug products are, in an overwhelming number of cases, produced as solid materials – for example, as tablets or granules in capsules. Even when formulated as liquids, the active pharmaceutical ingredient (API) is still usually produced as a solid prior to the final dissolution. During the development of a pharmaceutical formulation, knowledge of the physical properties of pharmaceutical materials – the APIs, the raw materials and the process intermediates for the API production, as well as the excipients and other chemicals for formulation – can help mitigate risks and offer opportunities for improved delivery. Knowledge of material properties is essential in a large number of activities when substances are brought in and out of the solid state, either as singular entities or as mixtures. Investigations into the effects of processes on materials present are termed ‘solid-state work’ and can have an effect during crystallization, dissolution, milling, drying, mixing, granulation, tableting, and so forth. Materials used in and obtained from these processes need to be characterized in a number of different ways, depending on what type of information is desired and on the properties of the material. For a solid-state scientist it is quite important to know which method of characterization to use for a particular material, how to design and run the instruments and how to use and evaluate the data from each technique. Unfortunately there is, to our knowledge, nowhere where a full academic education in pharmaceutical solid-state science is given; hence there is a continuous need for literature in this field.

One solid-state activity of special importance is the selection of the most suitable solid form of the API. This is a key solid-state process for successful scale-up and launch. Usually, a crystalline solid is desired because it provides an ideal solid for development due to its reproducible properties, such as solubility, and because it provides an excellent purification method during manufacture.

The form selection involves initial trials to crystallize the free form of the API, followed by salt-, co-crystal- and polymorph screening. Finally, the different solid phases obtained must be put on a thermodynamic stability scale so that the risks of future processing can be assessed without undesired surprises. It is critical that the correct solid form is selected for development as changes late in development and even in launch can affect the bioavailability of the API and hence its performance on dosing.

Solid form selection requires input from a wide number of disciplines including crystallization, stability assessment, biopharmaceutics, materials science and formulation, using a wide range of techniques, including high-throughput screening and computer predictions, for a successful nomination. Eventually, after the final selection has been made, patents covering some or perhaps all of the solid forms obtained during the selection work must be written.

Due to the importance of the different types of ‘solid-state work’ noted above, specifically the form selection, this book has been compiled to provide the reader with a single reference point. It incorporates an introduction to the crystalline state, a wide range of techniques for the

assessment of solid forms and chapters on their prediction, as well as the applicability of solid forms for patenting.

We hope that this book will provide the reader with a full toolbox for solid-state characterization and that the reader will have as much pleasure reading it as we have had producing it.

*Richard A. Storey*  
*Ingvar Ymén*

# 1

## Introduction to the Solid State – Physical Properties and Processes

*Ingvar Ymén*

*AstraZeneca R&D, Södertälje, Sweden*


### 1.1 Introduction

Pharmaceutical substances consist of organic molecules alone, or in combination with metal cations (metal salts), organic cations, organic or inorganic anions, neutral organic molecules (co-crystals) or solvent molecules (solvates). Even though some are salts, these have little resemblance with inorganic salts, the typical properties of which include high melting points, high hardness and strong ionic bonding. In fact, pharmaceutical substances, as salts or not, generally have similar properties, which are dominated by the presence of the organic molecules and their typical, weak intermolecular interactions. Crystals formed by organic substances are usually referred to as molecular crystals (Kitaigorodsky 1973) and it is the properties of this type of molecules that will be referred to when talking about the properties of pharmaceutical substances. In the following the physical states of a pure pharmaceutical substance will be discussed with reference to Figure 1.1 where the approximate areas of existence as a function of temperature are shown.

#### 1.1.1 The Gas/Vapour and Liquid States

A gas consists of molecules, moving independently of each other, but occasionally colliding with each other or with the vessel in which it is contained. The collisions make up the gas pressure and the more collisions the higher is the pressure. A gas containing small, point-like molecules with negligible molecular interactions is called ideal. For such a gas:

$$pV = nRT$$



**Figure 1.1** Different possible physical states of a pharmaceutical substance as a function of temperature; it is assumed that the pressure is constant at 1 atmosphere

where  $p$  = pressure,  $V$  = volume,  $n$  = the number of moles,  $T$  = temperature and  $R$  = the gas constant. Most gases are nonideal because their molecules are not pointlike and they interact to some extent. Gases at high temperatures are closest to ideal and the deviation from ideality increases closer to the point of condensation. In a mixture of ideal gases each gas will exert a pressure, which is proportional to the amount of that gas. The total pressure is the sum of the individual pressures so that for  $n$  different ideal gas molecules:

$$P_{\text{tot}} = p_1 + p_2 + \dots + p_n.$$

In a gas each molecule may interact with itself in an intramolecular way, thus forming various conformations. If the temperature of the gas is close to the condensation point, a certain conformation may be dominating but as the temperature of the gas increases the molecular vibrations and rotations increase. This leads to an increased number of conformations becoming available. Molecular structures of reasonably complex gaseous molecules are usually determined by means of gas-phase electron diffraction (Rankin and Robinson 1995) or microwave spectroscopy (Consalvo and Stahl 1998).

There can only be one gas phase, regardless of the number of different molecular species in it. Such a gas phase will be completely isotropic (have the same physical properties in all directions), have a very low density, low viscosity and a high compressibility.

Lowering the temperature, the gas molecules will gradually lose translational and vibrational/rotational energy. At a certain temperature, the condensation/boiling point, the molecules will, when colliding, start forming aggregates and a liquid will form. The temperature at which this occurs, depends on the size of the molecule and on the number and strength of the bonds formed. Small molecules, forming only weak intermolecular interactions, will have low boiling points whereas larger molecules, forming stronger, or a larger number of, intermolecular bonds have higher boiling points. It should be noted that the condensation process depends on seeds on which the drops of liquid can form. In the absence of seeds the vapour may be supercooled.

Upon condensation the entropy decreases and a latent enthalpy of condensation is given off, thus lowering the total energy of the liquid. The molecules in the liquid will, however, still have

energy enough to perform translational motion, but not enough to escape molecular interactions. Consequently molecular movement will no longer be independent. There will also be a tendency towards fewer molecular conformations and towards the formation of larger molecular entities, such as dimers. For this reason the molecules themselves are no longer completely randomly oriented. This short-range order in liquids can be analysed with small angle X-ray diffraction, SAXS (Klug and Alexander, 1974) and the presence of dimers and larger aggregates can be determined by spectroscopic methods (Spitaleri et al. 2004)). Still, the lack of long-range order makes all physical properties of liquids isotropic. These properties are, however, distinctly different from those of the gas.

A liquid at ambient conditions will establish equilibrium with its own gas phase, referred to as the liquids vapour (this word is sometimes also used to describe gases close to the condensation point). The pressure, which is a function of temperature, is called the vapour pressure. The maximum amount of vapour in equilibrium with liquid water at a certain temperature is called the saturation vapour pressure,  $p_{\text{sat}}$ . This pressure increases with increasing temperature and for water it becomes 101 kPa at 100 °C, the boiling point of water. Dividing the actual water vapour pressure,  $p_{\text{H}_2\text{O}}$  at a certain temperature with the saturation vapour pressure at the same temperature yields the relative humidity or the %RH:

$$\%RH = 100^* (p_{\text{H}_2\text{O}}/p_{\text{sat}}).$$

To avoid confusion one must always relate the %RH to temperature. The measurement of water vapour pressure in ambient air,  $p_{\text{H}_2\text{O}}$  is usually done as a dew point measurement (Moss 1934). An important difference between liquid and gas is that different liquids, when brought together, need not mix. Thus multiple liquid phases may be observed together, for instance in emulsions.

### 1.1.2 The Crystalline State


As a liquid is cooled the molecular movements decrease. Depending on the rate of cooling and on the properties of the liquid, either crystallization or glass formation will occur. For small, simple molecules at low cooling rates crystallization will normally occur at or below the freezing/melting point. There the molecules start forming intermolecular bonds, which are strong enough to stop translational, but not vibrational/rotational, motion. The freezing/melting point, like the boiling point, will be higher for larger molecules and for molecules with more and stronger interactions.

Upon crystallization the entropy decreases and a latent enthalpy of crystallization is released, which may be recorded as an exothermic event with, for instance, a DSC. Since crystallization is always more or less supercooled, an accurate determination of the theoretical onset temperature of crystallization (the freezing point) must instead be performed as a melting point analysis. The degree of super-cooling of the freezing point depends on molecular complexity and on presence of seeds.

The main similarity between the liquid and crystalline states is that, because the intermolecular distances are similar, the number of molecules per unit volume is roughly the same. This gives crystalline material numerical values of some physical properties, which are in a similar range to those of the liquid, for instance density and compressibility.

The big difference between liquids and crystals is the lack of translational motion and the presence of long-range order in crystals. In a crystal each molecule, with some exceptions (Dunitz and Gavezzotti 2005), has the same conformation and is fixed in one of a few possible, symmetry-related, positions. In this position, the molecule is bonded to its neighbours via weak intermolecular bonds (for example, hydrogen bonds or van der Waals bonds). In this way a crystal structure, which defines many of the physical properties, is formed.

The crystal structure may be described as a three-dimensional brick structure, built up of identical units cells, each of which is uniquely defined by its three unit cell axes  $a$ ,  $b$  and  $c$  and the three



**Figure 1.2** The unit cell with unit cell axes and angles indicated

**Table 1.1** The seven crystal systems

Crystal system	a	b	c	$\alpha$	$\beta$	$\gamma$
Triclinic	a	b	c	$\neq 90^*$	$\neq 90^*$	$\neq 90^*$
Monoclinic	a	b	c	90	$\neq 90$	90
Orthorhombic	a	b	c	90	90	90
Tetragonal	a	b	a	90	90	90
Trigonal	a	a	a	$\neq 90^*$	$\neq 90^*$	$\neq 90^*$
Hexagonal	a	b	a	90	120	90
Cubic	a	a	a	90	90	90

\*In the trigonal system all three angles are the same but in the triclinic they are all different.

angles  $\alpha$ ,  $\beta$ , and  $\gamma$ , between these axes (Figure 1.2). The combination of these axes and angles gives rise to seven possible crystal systems (Table 1.1). Any crystal structure can be described with a unit cell from one of the crystal systems.

The unit cell usually contains more than one molecule, and these molecules, if having the same conformation, are related to each other via symmetry operations, described by the space group (Giacovazzo 1992). The smallest part of the unit cell in which there is no symmetry is called the asymmetric unit (often only one molecule). The number of asymmetric units in the unit cell is denominated as  $Z$  and it is basically the number of different molecular conformations present in the crystals structure. There is a relation between  $Z$ , the unit cell volume  $V$ , the molecular weight  $M_w$ , Avogadro's number  $N_A$  and the density  $d$ :

$$d = ZM_w/VN_A$$

With this, densities are accurately calculated or, with an accurate density from, for example, pycnometry (Tamari and Aquilar-Chávez 2004) and a unit cell from X-ray data, the molecular weight can be checked.

In a crystal structure the molecules are packed efficiently and once the crystal structure is determined the packing efficiency can be calculated as the amount of filled space in the unit cell divided by the total unit cell volume. The value obtained is called the packing coefficient, which for organic molecules usually is in the range 0.65–0.73 (Kitaigorodsky 1973). Packing coefficients below 0.6 are rarely encountered.

Historically crystallography relied a lot on microscopy but today more than 99% is performed using X-rays together with either single crystals (SXRD) or a microcrystalline powder (XRPD). Table 1.2 lists a number of investigations, which can be performed by means of crystallography.

Both the crystal habit and the fracture of crystals are closely related to the crystal structure. Directions in the crystal structure where intermolecular bonding is weak will give rise to long unit cell axes and directions of stronger bonding give shorter axes. The crystal growth rate will

**Table 1.2** Typical crystallographic information obtained from single crystal X-ray diffraction (SXRD), X-ray powder diffraction (XRPD) and polarized light microscopy (PLM). Figures indicate which method is most suitable

Information searched	SXRD	XRPD	PLM
Is the sample crystalline or amorphous?	3*	1	2
What is the degree of crystallinity of the sample?		1	
Fingerprint identity of a single phase	3*	1	3
Is the sample a single phase?	3*	1	1
Quantify the amounts of several phases in a mixture		1	
Determination of crystal structure	1	2	
Unit cell data	1**	1**	
Optical data			1

\*SXRD uses one or a few single-crystals and will thus not give relevant information for larger microcrystalline samples.

\*\*It is usually easier to determine the unit cell using SXRD but XRPD gives a higher accuracy of the unit cell parameters. Therefore XRPD is often used to refine unit cell data obtained using SXRD.

be higher in the direction of stronger bonds, so a needle-shaped crystal will usually have the strongest bonds (a short unit cell axis) in the needle direction. Similarly, a very thin plate shaped crystal will have a long unit cell axis (weakest bonding direction) perpendicular to the plane of the plate. Likewise, when forces are applied on crystals they are likely to fracture along directions of weakest bonding, classical examples of which are talcum and graphite.

Control of crystal habit and of crystal size is of great importance, because these may have a large impact on material processing such as filtration, transport (flow properties), tableting, granulation and so forth. The most common ways to affect the crystal growth and habit are by choice of solvent and of supersaturation level for the crystallization. Moreover, because small amounts of foreign molecules may also have a large (usually negative) impact on both size and habit of crystals, it is common practice to purify materials as much as possible prior to crystallization. However, if done in a controlled way, the addition of small amounts of carefully selected substances may be beneficial both for habit modification and crystal size (Meenan et al. 2002).

The optical properties of crystals are also strongly related to the crystal structure and is more discussed by Bunn (1948).

### 1.1.3 The Glassy State

As noted above, depending on the rate of cooling and on the properties of the liquid, either crystallization or glass formation will occur. If a liquid containing comparably large and complex molecules, is cooled at a high rate the onset of crystallization might be severely overshot, resulting in the formation of a super-cooled liquid. Such a liquid will have a high viscosity, which upon continuous cooling eventually will become so high, that translational molecular movement will almost stop, at least compared to the time-scale of normal experiments. At this point the viscosity will be roughly  $10^{13}$  poise (Ediger et al. 1996) and a glass has formed.

A glass is often referred to as an amorphous material, which is somewhat ambiguous if one wants to distinguish it from a normal or a supercooled liquid. All three types of materials are in fact amorphous, meaning that they all lack the long-range order found in crystals. A comparison of the three by means of XRPD analysis shows that they all lack sharp peaks. Although lacking long-range order, amorphous materials usually have some short-range ordering such as the formation of hydrogen-bonded dimers, trimers and so forth in solutions of carboxylic acids.

Materials that are partially crystalline are sometimes observed. In XRPD-diffractograms this is indicated by an increased background level in some regions an/or as peak broadening (Klug and Alexander 1974). Partial crystallinity may be described by a one-phase model or a two-phase


model (Westdahl 1996), where the one-phase model assumes disorder in the crystalline material and the two-phase model assumes that the sample is a mixture of two phases, one completely crystalline and one completely amorphous. Which method is preferred depends on what type of material one is working with. For pharmaceutical substances the latter model is normally used. The degree of crystallinity may then be analysed with various techniques (Saleki-Gerhardt et al. 1994; Buckton and Darcy 1999).

Along the cooling process, from the melting point until the point of glass formation, all physical properties of the super-cooled liquid show the same gradual change upon cooling, as they do for the melt above the melting point. At the point of glass formation, the molecules have come so close together that this gradual change can no longer continue. Instead, upon continued cooling a different path is now followed so a new type of material has indeed appeared. The most common physical properties used to describe glass formation are the specific heat  $C_p$  or the specific volume  $V_{sp}$ , both of which show distinct changes when the glass forms (Figures 1.3 and 1.4).


The point of glass formation is called the glass transition temperature,  $T_g$ . Despite its name, it does not signify a true phase transition. Its value is not a constant but varies with the rate of cooling, so that the lower the rate, the lower the glass transition temperature and the lower the  $C_p$  and the  $V_{sp}$ . This is a consequence of the fact that at a slower rate the molecules have more time to pack more efficiently.

The glass transition is usually analysed using DSC and most conveniently using the modulated type. With a hot stage microscope, in heating mode,  $T_g$  can also be seen as the morphological change from a chip-like solid to a rounded liquid drop.

The glass transition temperature can also be affected by impurities and will in many cases drop significantly by the uptake of water. This is the basis for the determination of the amount of



**Figure 1.3** Variation of  $C_p$  as a function of temperature for a liquid that becomes a glass; the effect of different cooling-rates  $v_1$ ,  $v_2$  and  $v_3$ , is also indicated



**Figure 1.4** Variation of  $V_{sp}$  as a function of temperature for a liquid that becomes a glass; the effect of different cooling-rates  $v_1$  and  $v_2$ , is also indicated

glass in a sample, using isothermal calorimeters (Ahlneck et al. 1994). The material is allowed to take up water so that  $T_g$  gradually drops. Crystallization occurs when it reaches the temperature of the calorimeter. The heat of crystallization is proportional to the amount of glass present in the sample. Since grinding of pharmaceutical substances often destroys parts of the crystal structure, amorphous material may be formed upon milling or grinding. The isothermal calorimeter measurements described above works very well for the quantification of the amount of amorphous material thus formed (Buckton et al. 1994).

The best analyses for the identification of a glass are polarized light microscopy (indicates optically isotropic behaviour), XRPD (no peaks) and DSC (shows  $T_g$ ).

Other methods, such as isothermal calorimetry, moisture sorption and spectroscopic methods, will not offer identification on their own but they are good complimentary methods.


## 1.2 Neutral Pharmaceutical Molecules

Figure 1.5 shows a typical hypothetical, neutral pharmaceutical molecule in which different parts or groups are circled. What parts are present and how these are combined will determine the molecular properties and at the macroscopic level also the physical properties of the substance. Some fundamental molecular properties of importance from the solid-state perspective will be discussed below.

In a pharmaceutical molecule the groups with the lowest or highest  $pK_A$  values can be exploited when preparing salts. The molecule in Figure 1.5 has a typically acidic group, a carboxylic acid and a typically alkaline group, a secondary amine. These groups will be responsible for the main protolytic properties of the molecule – that is, they will have the highest and the lowest  $pK_A$  values. In fact, a substance like this, having both an acidic and an alkaline group, may establish an internal acid – base equilibrium and thus behave as a zwitterions in the pH range between the two  $pK_A$ -values.

The  $pK_A$  value of an isolated functional group is usually easy to predict from the approximate ranges given in an organic chemistry textbook. However, when neighbouring groups interact, by means of resonance, inductive effects and so forth, things become more difficult. Database computer programs may be used to assist but, to be on the safe side, experimental  $pK_A$ -determinations should be made by acid-base titrations or NMR analysis (Kubal et al. 1994). It should be noted that  $pK_A$ -values, which are usually measured in water solutions, can also be determined in nonaqueous solvents, wherein they will take different values (Barcza and Buvári-Barcza 2003).

Some pharmaceutical molecules are very soluble in water but not in oil whereas others behave in more-or-less the opposite way. This type of behaviour is expressed by means of the partition coefficient between oil and water,  $K_p$ , which measures the molecules' approximate affinity for



**Figure 1.5** A hypothetical pharmaceutical molecule with various functionalities marked

water and for oil. A molecule with a high affinity for water is referred to as hydrophilic and one with a high affinity for oil as hydrophobic. On a molecular level the main difference between water and oil is the dipole moments of the molecules, that of water being quite high and that of a typical molecule in oil being low. This is the main reason for the high dielectricity constant of water compared to oil. Since most oils almost entirely consist of hydrocarbons it should be clear that hydrocarbon groups in a molecule are hydrophobic. A typical such part is circled in the leftmost side of Figure 1.5.

The parts of the molecule, which have local, high dipole moments, that is, groups in which there are local large charge separations, will be hydrophilic. Such areas are marked with dark circles in Figure 1.5. The fact that the molecule has one hydrophobic and one hydrophilic end means that it is very likely to have surface-active properties. At the interface between a hydrophilic and a hydrophobic medium, it will thus orient itself with its hydrophobic end towards the hydrophobic medium and the hydrophilic end towards the hydrophilic.

The number, size and position of the various hydrophilic and hydrophobic areas of a molecule will be responsible for 'the molecular part' of the solubility of a crystalline substance in a certain solvent (Yalkowsky and Banerjee 1992). This part mainly accounts for how well the molecules fit in and interact with the solvent molecules and is related to the partition coefficient. The other part, which determines the solubility of a substance is 'the crystal structure part', defined by how well the molecules interact in a crystal structure. This part has a strong relation to the melting point. Computer programs aiming to predict solubility solely from the knowledge about molecular structure have so far, for this reason, had limited success.

The density of pharmaceutical substances depends on the molecular density (molecular weight/molecular volume) and on how well the molecules pack in the solid (see packing coefficient in 1.4). The molecular density is usually the same for substances containing only C, H, N and O, the crystal density of which usually are between 1.2–1.4 kg/l. With the presence of heavier elements such as Si, S, P and halogens the molecular and crystal density typically increase.

The lowest energy conformation of a hypothetical molecule in a state without any interactions with other molecules can be calculated by means of quantum mechanics 'in vacuum' (Leach 2001). This conformation will be a consequence of the molecule's ambition to lower its total energy by minimizing steric effects and optimizing intramolecular bonding. Steric effects may be overcome if the molecule has enough flexibility, that is, low energy rotational bonds. From the bonding perspective the molecule strives to maximize the number and strength of the bonds formed. The formation of strong intramolecular hydrogen bonds may complicate the molecular analysis. These form between hydrogen bond donors (groups containing circled hydrogen atoms in Figure 1.5) and hydrogen bond acceptors (circled O- and N-atoms in the figure). If the molecule is large, folding so as to maximize van der Waals contacts might also become very important, as will interactions involving  $\pi$ -systems. The central aromatic system in Figure 1.5 will be quite inflexible and essentially planar. Quite possibly, in vacuum the terminal unsaturated hydrocarbon chain would fold over the central aromatic ring system so as to optimize  $\pi - \pi$  interactions.

Today, quantum chemical modelling may also involve solvent, explicitly or implicitly, allowing more adequate data to be compared to experimental results in solution. However, in many cases theoretical models may fail to properly represent real liquid or solid pharmaceutical systems.

The absorption of visible and ultraviolet light in neutral pharmaceutical molecules is due to the presence of 'chromophores'. These are unsaturated parts of molecules containing multiple bonds. In Figure 1.5 there are many parts that act as chromophores, the unsaturated carbohydrate chain, the central aromatic ring system and the carboxylic acid. Coloured solid pharmaceutical substances usually contain large chromophore systems, in which there are many possible resonance structures.